We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

86 hedge funds and large institutions have $663M invested in Adaptimmune Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

219% more call options, than puts

Call options by funds: $2.08M | Put options by funds: $654K

83% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 12

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

13% more funds holding

Funds holding: 76 → 86 (+10)

5% more capital invested

Capital invested by funds: $631M → $663M (+$32.9M)

0.11% less ownership

Funds ownership: 9.99% → 9.88% (-0.11%)

23% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 26

Holders
86
Holders Change
+10
Holders Change %
+13.16%
% of All Funds
1.97%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.11%
New
22
Increased
20
Reduced
26
Closed
12
Calls
$2.08M
Puts
$654K
Net Calls
+$1.43M
Net Calls Change
+$1.69M

Top Buyers

Rank Fund Capital Flow
1
DWA
Dorsey Wright & Associates
California
+$7.29M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$5.83M
3
Capital World Investors
Capital World Investors
California
+$4.91M
4
BAMCO Inc
BAMCO Inc
New York
+$4.31M
5
FCMI
Foresite Capital Management II
California
+$3.74M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$7.84M
2
Fidelity International
Fidelity International
Bermuda
-$7.49M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.03M
4
QF
QVT Financial
New York
-$4.49M
5
GAMA
Graticule Asia Macro Advisors
New York
-$4.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
EIM
26
Essex Investment Management
Massachusetts
$2M -$2.57M -205,830 -55%
Lazard Asset Management
27
Lazard Asset Management
New York
$1.91M +$614K +49,210 +44%
FCM
28
Frontier Capital Management
Massachusetts
$1.84M +$1.93M +154,885 New
Deutsche Bank
29
Deutsche Bank
Germany
$1.56M -$2.55M -204,193 -61%
Citadel Advisors
30
Citadel Advisors
Florida
$1.34M +$1.41M +113,280 New
NIMI
31
Natixis Investment Managers International
France
$1.25M +$1.32M +105,477 New
Creative Planning
32
Creative Planning
Kansas
$1.22M +$49.9K +4,000 +4%
BBA
33
Baker Bros. Advisors
New York
$1.19M – – –
GAMA
34
Graticule Asia Macro Advisors
New York
$950K -$4.2M -336,457 -81%
WMSA
35
Weiss Multi-Strategy Advisers
New York
$950K – – –
Arrowstreet Capital
36
Arrowstreet Capital
Massachusetts
$815K +$26.2K +2,100 +3%
VEA
37
Virtus ETF Advisers
New York
$774K +$813K +65,221 New
BG
38
Bellevue Group
Switzerland
$711K +$747K +59,935 New
PCM
39
Prelude Capital Management
New York
$628K -$583K -46,796 -47%
Squarepoint
40
Squarepoint
New York
$596K +$108K +8,700 +21%
DADC
41
D.A. Davidson & Co
Montana
$585K -$16.8K -1,347 -3%
PA
42
Perceptive Advisors
New York
$585K +$615K +49,302 New
Goldman Sachs
43
Goldman Sachs
New York
$491K -$178K -14,313 -26%
Geode Capital Management
44
Geode Capital Management
Massachusetts
$487K -$25.9K -2,074 -5%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$449K +$471K +37,796 New
State Street
46
State Street
Massachusetts
$431K -$18.5K -1,480 -4%
Barclays
47
Barclays
United Kingdom
$417K -$10.5K -840 -2%
RJFSA
48
Raymond James Financial Services Advisors
Florida
$379K +$164K +13,151 +70%
ProShare Advisors
49
ProShare Advisors
Maryland
$328K -$29.9K -2,399 -8%
TAM
50
Tocqueville Asset Management
New York
$311K +$326K +26,175 New
1
2
3 4

ADAP Hedge Fund Activity: Q2 2018 in Review

86 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2018, worth a combined $663M — up 5.2% from $631M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ADAP positions and 12 closed out — a net gain of 10 holders — while 20 added to existing stakes and 26 trimmed.

The largest buyer was Dorsey Wright & Associates, opening a new position worth an estimated $7.29M. The largest seller was Millennium Management, cutting an estimated $7.84M.

  • 86 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2018, up from 76 in Q1 2018.
  • Funds reported $663M of Adaptimmune Therapeutics stock for Q2 2018, up 5.2% quarter-over-quarter.
  • 22 funds opened new Adaptimmune Therapeutics positions in Q2 2018 and 12 closed out, a net change of +10 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2018 was Dorsey Wright & Associates, an estimated $7.29M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2018 was Millennium Management, an estimated $7.84M sold.

Based on aggregated 13F filings for Q2 2018.